Compare Dr. Reddys with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs BIOCON - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB BIOCON DR. REDDYS LAB/
BIOCON
 
P/E (TTM) x 36.6 29.0 126.0% View Chart
P/BV x 4.3 3.3 130.3% View Chart
Dividend Yield % 0.6 0.3 184.4%  

Financials

 DR. REDDYS LAB   BIOCON
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
BIOCON
Mar-19
DR. REDDYS LAB/
BIOCON
5-Yr Chart
Click to enlarge
High Rs2,875707 406.5%   
Low Rs1,888554 340.9%   
Sales per share (Unadj.) Rs930.291.9 1,012.1%  
Earnings per share (Unadj.) Rs117.416.7 702.7%  
Cash flow per share (Unadj.) Rs185.824.2 768.4%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.80.2 529.5%  
Book value per share (Unadj.) Rs844.4101.6 830.9%  
Shares outstanding (eoy) m166.07600.00 27.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.66.9 37.3%   
Avg P/E ratio x20.337.7 53.7%  
P/CF ratio (eoy) x12.826.1 49.2%  
Price / Book Value ratio x2.86.2 45.5%  
Dividend payout %17.06.0 284.6%   
Avg Mkt Cap Rs m395,496378,330 104.5%   
No. of employees `00022.06.1 358.3%   
Total wages/salary Rs m33,56211,653 288.0%   
Avg. sales/employee Rs Th7,032.88,994.3 78.2%   
Avg. wages/employee Rs Th1,527.91,900.7 80.4%   
Avg. net profit/employee Rs Th887.71,635.3 54.3%   
INCOME DATA
Net Sales Rs m154,48255,144 280.1%  
Other income Rs m3,3751,444 233.7%   
Total revenues Rs m157,85756,588 279.0%   
Gross profit Rs m31,78215,883 200.1%  
Depreciation Rs m11,3484,478 253.4%   
Interest Rs m889709 125.4%   
Profit before tax Rs m22,92012,140 188.8%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8582,123 181.7%   
Profit after tax Rs m19,50010,026 194.5%  
Gross profit margin %20.628.8 71.4%  
Effective tax rate %16.817.5 96.3%   
Net profit margin %12.618.2 69.4%  
BALANCE SHEET DATA
Current assets Rs m111,10148,228 230.4%   
Current liabilities Rs m58,97330,376 194.1%   
Net working cap to sales %33.732.4 104.2%  
Current ratio x1.91.6 118.7%  
Inventory Days Days7968 116.2%  
Debtors Days Days9486 110.2%  
Net fixed assets Rs m101,24564,130 157.9%   
Share capital Rs m8303,000 27.7%   
"Free" reserves Rs m139,40657,980 240.4%   
Net worth Rs m140,23660,980 230.0%   
Long term debt Rs m22,00015,766 139.5%   
Total assets Rs m224,656121,924 184.3%  
Interest coverage x26.818.1 147.8%   
Debt to equity ratio x0.20.3 60.7%  
Sales to assets ratio x0.70.5 152.0%   
Return on assets %9.18.8 103.1%  
Return on equity %13.916.4 84.6%  
Return on capital %14.916.8 89.2%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m88,67315,506 571.9%   
Fx outflow Rs m19,10410,399 183.7%   
Net fx Rs m69,5695,107 1,362.2%   
CASH FLOW
From Operations Rs m28,70411,546 248.6%  
From Investments Rs m-7,727-7,138 108.3%  
From Financial Activity Rs m-21,326-2,417 882.3%  
Net Cashflow Rs m-3142,103 -14.9%  

Share Holding

Indian Promoters % 25.5 40.4 63.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.4 8.4 64.3%  
FIIs % 35.3 10.7 329.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 19.9 76.9%  
Shareholders   75,885 109,995 69.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

This Smallcap Tech Firm has Risen to the Coronavirus Challenge(Profit Hunter)

Apr 7, 2020

This smallcap tech firm is all set to emerge stronger from the Coronavirus crisis.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 9, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS